Lopes, RaquelFerreira, Bruna VelosaCaetano, JoanaBarahona, FilipaCarneiro, Emilie ArnaultJoão, Cristina2021-04-232021-04-232021-03-022072-6694PURE: 29161605PURE UUID: 4195fb97-6692-4e64-9f14-b6de77d32a4cScopus: 85103360225PubMed: 33799565WOS: 000634340400001http://hdl.handle.net/10362/116085Funding: This research was funded by Fundação para a Ciência e Tecnologia (FCT), PTDC/MECHEM/30315/2017 and UIDB/04443/2020Despite the improvement of patient’s outcome obtained by the current use of immunomod-ulatory drugs, proteasome inhibitors or anti-CD38 monoclonal antibodies, multiple myeloma (MM) remains an incurable disease. More recently, the testing in clinical trials of novel drugs such as anti-BCMA CAR-T cells, antibody–drug conjugates or bispecific antibodies broadened the possibility of improving patients’ survival. However, thus far, these treatment strategies have not been able to steadily eliminate all malignant cells, and the aim has been to induce a long-term complete response with minimal residual disease (MRD)-negative status. In this sense, approaches that target not only myeloma cells but also the surrounding microenvironment are promising strategies to achieve a sustained MRD negativity with prolonged survival. This review provides an overview of current and future strategies used for immunomodulation of MM focusing on the impact on bone marrow (BM) immunome.211405295engBone marrow immune microenvironmentImmunotherapyMultiple myelomaOncologyCancer ResearchSDG 3 - Good Health and Well-beingreview10.3390/cancers13061221https://www.scopus.com/pages/publications/85103360225